The India COPD Therapeutics Market was valued at $332 Mn in 2022 and is estimated to expand at a CAGR of 10.1% from 2022 to 2030 and will reach $717 Mn in 2030. One of the main reasons propelling the growth of this market is increase prevalence rate, government initiative. The market is segmented by Drug class and by distribution channel. Some key players in this market are Cipla, Glenmark Pharmaceuticals, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva India Limited and others.
The India Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market was valued at $332 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.1% from 2022 to 2030 and will reach $717 Mn in 2030. Chronic Obstructive Pulmonary Disease (COPD) is a "common preventable, and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation due to abnormalities in the airway and (or) alveolar abnormalities usually caused by significant exposure to noxious particles or gases”. The World Health Organization (WHO) lists COPD as one of the major causes of death worldwide. The reduction of the global burden of respiratory diseases is a shared commitment of the WHO Global Partnership against Chronic Respiratory Disorders. Due to expensive medical expenses and a reduced quality of life related to one's health, COPD also places a heavy burden on society. It is the most common chronic respiratory disease to cause impairment and was the second-leading cause of Disability Adjusted Life Years (DALY) in 2016.
The prevalence of COPD (chronic obstructive pulmonary disease) is highest in India. The number climbed from 28.1 million in the 1990s to 55.3 million in 2016, according to the Lancet Respiratory Medicine article. According to the Indian Study on Epidemiology of Asthma, Respiratory Symptoms, and Chronic Bronchitis in Adults, India significantly contributes to the morbidity and mortality of COPD in the world, with 3% of India's disability-adjusted life years (DALYs) being recorded due to chronic respiratory diseases (CRDs) (INSEARCH). The primary cause of CRDs is COPD, which must be noted and understood. Several studies estimate that the yearly economic cost of COPD to be more than 48,000 crores, which is significantly greater than the Ministry of Health and Family Welfare's annual budget (MOHFW) of 2010-2011.
Market Growth Drivers
According to a study published in the Journal of Family Medicine and Primary Care India in 2020, the prevalence of COPD in is around 4.2%. The study also projected that the prevalence of COPD in India will continue to increase in the coming years, primarily due to rising smoking rates, air pollution, and aging population. This increasing prevalence of COPD is driving the demand for COPD therapeutics in India. The Indian government and various organizations have been taking steps to raise awareness about COPD and its risk factors. For instance, the Indian Chest Society launched the "Breathefree" initiative in 2012 to increase awareness about COPD and provide access to affordable COPD therapeutics. This rising awareness about COPD is expected to drive the demand for COPD therapeutics in India. Government initiatives: The Indian government has taken several initiatives to promote the use of COPD therapeutics in the country. For instance, in 2020, the Ministry of Health and Family Welfare launched the "National Chronic Obstructive Pulmonary Disease (COPD) Program" to improve the diagnosis and treatment of COPD in the country. This initiative is expected to drive the demand for COPD therapeutics in India. Growing healthcare infrastructure: India has been investing heavily in improving its healthcare infrastructure in recent years. According to a report, India's healthcare market is expected to grow at a CAGR of 22% between 2020 and 2025. This growing healthcare infrastructure is expected to increase access to COPD therapeutics in India and drive the growth of the India COPD therapeutics market. Several players in the India COPD therapeutics market are focusing on developing new and innovative COPD therapeutics. For instance, in 2020, Glenmark Pharmaceuticals launched a new inhaler for the treatment of COPD in India. This product innovation is expected to drive the demand for COPD therapeutics in India.
Despite efforts by the government and various organizations, many people in India are still not aware of COPD and its risk factors. This lack of awareness can lead to underdiagnosis and undertreatment of COPD, which can hinder the growth of the India COPD therapeutics market. COPD therapeutics can be expensive, especially for patients who require long-term treatment. Many people in India may not be able to afford the cost of COPD therapeutics, which can limit the demand for these drugs. Despite the growing healthcare infrastructure in India, many people still have limited access to healthcare, especially in rural areas. This limited access to healthcare can make it difficult for people with COPD to receive timely and adequate treatment, which can hinder the growth of the India COPD therapeutics market. In addition to COPD therapeutics, there are several alternative therapies available for the treatment of COPD, such as traditional medicines and home remedies. These alternative therapies can compete with COPD therapeutics and limit the growth of the India COPD therapeutics market. The Indian regulatory environment for pharmaceuticals is known to be strict, and companies must adhere to strict regulations to obtain approval for their products. This can increase the cost and time required for product development and hinder the growth of the India COPD therapeutics market.
The Ministry of Health and Family Welfare is responsible for formulating and implementing healthcare policies in India. The ministry oversees several departments, including the Department of Health and the Department of Family Welfare.
Central Drugs Standard Control Organization (CDSCO) responsible for regulating the import, manufacture, distribution, and sale of pharmaceuticals in India. The organization is responsible for granting approvals for drugs, medical devices, and clinical trials. National Pharmaceutical Pricing Authority (NPPA) is responsible for fixing and regulating the prices of drugs in India. The organization ensures that the prices of essential drugs are affordable and accessible to all. Drugs Controller General of India (DCGI) is responsible for regulating the safety, efficacy, and quality of drugs in India. The organization oversees the approval of new drugs, clinical trials, and post-marketing surveillance.
Indian Pharmacopoeia Commission (IPC) is responsible for setting standards for drugs in India. The commission develops and publishes the Indian Pharmacopoeia, which is a book of standards for drugs in India. The government has taken several initiatives to improve the healthcare system in India, including the launch of the Ayushman Bharat scheme, which aims to provide free healthcare to millions of people in India.
In general, COPD treatment in India is covered by both public and private insurance schemes, but the reimbursement rates vary widely. Public insurance schemes, such as the Rashtriya Swasthya Bima Yojana (RSBY) and Ayushman Bharat, provide coverage for COPD treatment, but the reimbursement rates may not cover the full cost of treatment. Private insurance schemes may provide more comprehensive coverage, but the premiums can be expensive and not all individuals have access to private insurance. In addition, the reimbursement scenario for COPD treatment can vary depending on the type of healthcare provider. Treatment in government hospitals and clinics may be more affordable and accessible for low-income individuals, but these facilities may have limited resources and long wait times. Private healthcare providers may offer more personalized care and better facilities, but the costs can be higher.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
126.96.36.199 Product Applications and Services
188.8.131.52 Recent Developments
184.108.40.206 Partnerships Ecosystem
220.127.116.11 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Class
Bronchodilators: Bronchodilators are medications that help to relax the muscles around the airways, making it easier to breathe. These can be further classified as short-acting or long-acting bronchodilators.
Corticosteroids: Corticosteroids are anti-inflammatory medications that can help reduce swelling and inflammation in the airways. These can be used alone or in combination with bronchodilators.
Combination therapies: Combination therapies combine bronchodilators and corticosteroids in a single medication. These are often used for patients with more severe COPD.
Phosphodiesterase-4 inhibitors: Phosphodiesterase-4 inhibitors are medications that help to reduce inflammation and improve airflow in the lungs.
Others: Other medications that may be used to treat COPD include mucolytics, oxygen therapy, and vaccines for influenza and pneumococcal disease.
By Distribution Channel:
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses